Robert E. Gagnon, Chief Financial Officer of Opus Genetics, Inc., filed a Form 4 on October 27, 2026, reporting the sale of 14,000 shares of common stock on October 23, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Robert E. Gagnon, Chief Financial Officer of Opus Genetics, Inc. (NASDAQ:IRD)
  • Shares sold: 14,000 shares of common stock disposed of (transaction code S) on October 23, 2026
  • Weighted average price: $3.5464 per share, with individual transactions ranging from $3.4449 to $3.79, inclusive
  • Remaining ownership: 542,375 shares of common stock beneficially owned directly following the transaction
  • Rule 10b5-1 plan: Sales were made under a trading plan adopted by Gagnon on April 30, 2026
  • Purpose stated: According to the filing, the shares sold cover tax withholding obligations arising from the vesting and settlement of restricted stock units

Gagnon's October 2026 Share Sale: Tax Withholding Under a 10b5-1 Plan

According to the Form 4 filed with the SEC on October 27, 2026, Robert E. Gagnon, the Chief Financial Officer of Opus Genetics, Inc. (NASDAQ:IRD), sold 14,000 shares of the company's common stock on October 23, 2026. The sale was executed under a Rule 10b5-1 trading plan that Gagnon adopted on April 30, 2026. The filing also checked the box indicating the transaction was made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

The filing states that the reported transaction "does not represent a discretionary trade by the Reporting Person." The shares were sold in multiple transactions at prices ranging from $3.4449 to $3.79, inclusive, with a weighted average price of $3.5464. The filing further states that the shares sold "cover tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units." Gagnon undertook to provide, upon request, full information regarding the number of shares sold at each separate price within the stated range.

Following the reported transaction, Gagnon directly held 542,375 shares of Opus Genetics common stock. No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Amy Rabourn, by Power of Attorney, on October 27, 2026.

What Was Disclosed

Opus Genetics CFO Robert E. Gagnon reported the sale of 14,000 common shares on October 23, 2026, at a weighted average price of $3.5464, under a Rule 10b5-1 plan adopted April 30, 2026, to cover RSU-related tax withholding obligations. He retained 542,375 shares directly after the sale.